# L_2021188EN.01002701.xml

| 28.5.2021 | EN | Official Journal of the European Union | L 188/27 |
| --- | --- | --- | --- |

28.5.2021

EN

Official Journal of the European Union

L 188/27

---

COMMISSION DELEGATED REGULATION (EU) 2021/849

of 11 March 2021

amending, for the purposes of its adaptation to technical and scientific progress, Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (1), and in particular Article 37(5) thereof,

Whereas:

| (1) | Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains the list of harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to that Regulation. |
| --- | --- |

(1)

Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains the list of harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to that Regulation.

| (2) | Proposals to introduce harmonised classification and labelling of certain substances and to update or delete the harmonised classification and labelling of certain other substances have been submitted to the European Chemicals Agency (‘Agency’) pursuant to Article 37 of Regulation (EC) No 1272/2008. The Committee for Risk Assessment of the Agency (RAC) adopted opinions (2) on those proposals, after having taken account of the comments received from the parties concerned. Those RAC opinions are:






  — | Opinion of 15 March 2019 concerning 1,2,4-triazole, |
| --- | --- | --- |

(2)

Proposals to introduce harmonised classification and labelling of certain substances and to update or delete the harmonised classification and labelling of certain other substances have been submitted to the European Chemicals Agency (‘Agency’) pursuant to Article 37 of Regulation (EC) No 1272/2008. The Committee for Risk Assessment of the Agency (RAC) adopted opinions (2) on those proposals, after having taken account of the comments received from the parties concerned. Those RAC opinions are:

—

Opinion of 15 March 2019 concerning 1,2,4-triazole,

| — | Opinion of 15 March 2019 concerning 1,4-dioxane, |
| --- | --- |

—

Opinion of 15 March 2019 concerning 1,4-dioxane,

| — | Opinion of 15 March 2019 concerning benzyl salicylate, |
| --- | --- |

—

Opinion of 15 March 2019 concerning benzyl salicylate,

| — | Opinion of 15 March 2019 concerning flumioxazin (ISO), |
| --- | --- |

—

Opinion of 15 March 2019 concerning flumioxazin (ISO),

| — | Opinion of 15 March 2019 concerning mancozeb (ISO), |
| --- | --- |

—

Opinion of 15 March 2019 concerning mancozeb (ISO),

| — | Opinion of 15 March 2019 concerning M-factors for long-term aquatic hazard for the copper substances listed in Commission Regulation (EU) 2016/1179, |
| --- | --- |

—

Opinion of 15 March 2019 concerning M-factors for long-term aquatic hazard for the copper substances listed in Commission Regulation (EU) 2016/1179,

| — | Opinion of 15 March 2019 concerning N-{2-[[1,1'-bi(cyclopropyl)]-2-yl]phenyl}-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide; sedaxane, |
| --- | --- |

—

Opinion of 15 March 2019 concerning N-{2-[[1,1'-bi(cyclopropyl)]-2-yl]phenyl}-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide; sedaxane,

| — | Opinion of 15 March 2019 concerning N-methoxy-N-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide; pydiflumetofen, |
| --- | --- |

—

Opinion of 15 March 2019 concerning N-methoxy-N-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide; pydiflumetofen,

| — | Opinion of 15 March 2019 concerning p-cymene; 1-isopropyl-4-methylbenzene, |
| --- | --- |

—

Opinion of 15 March 2019 concerning p-cymene; 1-isopropyl-4-methylbenzene,

| — | Opinion of 15 March 2019 concerning p-mentha-1,3-diene; alpha-terpinene; 1-isopropyl-4-methylcyclohexa-1,3-diene, |
| --- | --- |

—

Opinion of 15 March 2019 concerning p-mentha-1,3-diene; alpha-terpinene; 1-isopropyl-4-methylcyclohexa-1,3-diene,

| — | Opinion of 15 March 2019 concerning prothioconazole, |
| --- | --- |

—

Opinion of 15 March 2019 concerning prothioconazole,

| — | Opinion of 15 March 2019 concerning (R)-p-mentha-1,8-diene; d-limonene, |
| --- | --- |

—

Opinion of 15 March 2019 concerning (R)-p-mentha-1,8-diene; d-limonene,

| — | Opinion of 15 March 2019 concerning thiophanate-methyl, |
| --- | --- |

—

Opinion of 15 March 2019 concerning thiophanate-methyl,

| — | Opinion of 15 March 2019 concerning tolclofos-methyl (ISO); O-(2,6-dichloro-p-tolyl) O,O-dimethyl thiophosphate, |
| --- | --- |

—

Opinion of 15 March 2019 concerning tolclofos-methyl (ISO); O-(2,6-dichloro-p-tolyl) O,O-dimethyl thiophosphate,

| — | Opinion of 15 March 2019 concerning tolpyralate, |
| --- | --- |

—

Opinion of 15 March 2019 concerning tolpyralate,

| — | Opinion of 15 March 2019 concerning trinickel disulphide, |
| --- | --- |

—

Opinion of 15 March 2019 concerning trinickel disulphide,

| — | Opinion of 13 June 2019 concerning azamethiphos, |
| --- | --- |

—

Opinion of 13 June 2019 concerning azamethiphos,

| — | Opinion of 13 June 2019 concerning 2-phenoxyethanol, |
| --- | --- |

—

Opinion of 13 June 2019 concerning 2-phenoxyethanol,

| — | Opinion of 13 June 2019 concerning 2,2-dibromo-2-cyanoacetamide, |
| --- | --- |

—

Opinion of 13 June 2019 concerning 2,2-dibromo-2-cyanoacetamide,

| — | Opinion of 13 June 2019 concerning 3-aminomethyl-3,5,5-trimethylcyclohexylamine, |
| --- | --- |

—

Opinion of 13 June 2019 concerning 3-aminomethyl-3,5,5-trimethylcyclohexylamine,

| — | Opinion of 13 June 2019 concerning 6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol, |
| --- | --- |

—

Opinion of 13 June 2019 concerning 6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol,

| — | Opinion of 13 June 2019 concerning diflufenican (ISO) N-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide, |
| --- | --- |

—

Opinion of 13 June 2019 concerning diflufenican (ISO) N-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide,

| — | Opinion of 13 June 2019 concerning imidacloprid (ISO); 1-(6-chloropyridin-3-ylmethyl)-N-nitroimidazolidin-2-ylidenamine, |
| --- | --- |

—

Opinion of 13 June 2019 concerning imidacloprid (ISO); 1-(6-chloropyridin-3-ylmethyl)-N-nitroimidazolidin-2-ylidenamine,

| — | Opinion of 13 June 2019 concerning pyriofenone, |
| --- | --- |

—

Opinion of 13 June 2019 concerning pyriofenone,

| — | Opinion of 13 June 2019 concerning S-abscisic acid, |
| --- | --- |

—

Opinion of 13 June 2019 concerning S-abscisic acid,

| — | Opinion of 13 June 2019 concerning tetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate, |
| --- | --- |

—

Opinion of 13 June 2019 concerning tetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate,

| — | Opinion of 20 September 2019 concerning 1,2-epoxy-4-epoxyethylcyclohexane, |
| --- | --- |

—

Opinion of 20 September 2019 concerning 1,2-epoxy-4-epoxyethylcyclohexane,

| — | Opinion of 20 September 2019 concerning 4-methylpentan-2-one, |
| --- | --- |

—

Opinion of 20 September 2019 concerning 4-methylpentan-2-one,

| — | Opinion of 20 September 2019 concerning boric acid; diboron trioxide; tetraboron disodium heptaoxide hydrate; disodium tetraborate anhydrous; orthoboric acid sodium salt; disodium tetraborate decahydrate; disodium tetraborate pentahydrate, |
| --- | --- |

—

Opinion of 20 September 2019 concerning boric acid; diboron trioxide; tetraboron disodium heptaoxide hydrate; disodium tetraborate anhydrous; orthoboric acid sodium salt; disodium tetraborate decahydrate; disodium tetraborate pentahydrate,

| — | Opinion of 20 September 2019 concerning citric acid, |
| --- | --- |

—

Opinion of 20 September 2019 concerning citric acid,

| — | Opinion of 20 September 2019 concerning clomazone, |
| --- | --- |

—

Opinion of 20 September 2019 concerning clomazone,

| — | Opinion of 20 September 2019 concerning desmedipham, |
| --- | --- |

—

Opinion of 20 September 2019 concerning desmedipham,

| — | Opinion of 20 September 2019 concerning dimethomorph, |
| --- | --- |

—

Opinion of 20 September 2019 concerning dimethomorph,

| — | Opinion of 20 September 2019 concerning emamectin benzoate, |
| --- | --- |

—

Opinion of 20 September 2019 concerning emamectin benzoate,

| — | Opinion of 20 September 2019 concerning esfenvalerate (ISO) (S)-α-cyano-3-phenoxybenzyl (S)-2-(4-chlorophenyl)-3-methylbutyrate, |
| --- | --- |

—

Opinion of 20 September 2019 concerning esfenvalerate (ISO) (S)-α-cyano-3-phenoxybenzyl (S)-2-(4-chlorophenyl)-3-methylbutyrate,

| — | Opinion of 20 September 2019 concerning ethametsulfuron-methyl (ISO), |
| --- | --- |

—

Opinion of 20 September 2019 concerning ethametsulfuron-methyl (ISO),

| — | Opinion of 20 September 2019 concerning mecoprop-P (ISO); (R)-2-(4-chloro-2-methylphenoxy)propionic acid and its salts, |
| --- | --- |

—

Opinion of 20 September 2019 concerning mecoprop-P (ISO); (R)-2-(4-chloro-2-methylphenoxy)propionic acid and its salts,

| — | Opinion of 20 September 2019 concerning methyl salicylate, |
| --- | --- |

—

Opinion of 20 September 2019 concerning methyl salicylate,

| — | Opinion of 20 September 2019 concerning phenmedipham (ISO), |
| --- | --- |

—

Opinion of 20 September 2019 concerning phenmedipham (ISO),

| — | Opinion of 20 September 2019 concerning trifloxystrobin (ISO), |
| --- | --- |

—

Opinion of 20 September 2019 concerning trifloxystrobin (ISO),

| — | Opinion of 20 September 2019 concerning triticonazole, |
| --- | --- |

—

Opinion of 20 September 2019 concerning triticonazole,

| — | Opinion of 5 December 2019 concerning 1,4-dimethylnaphthalene, |
| --- | --- |

—

Opinion of 5 December 2019 concerning 1,4-dimethylnaphthalene,

| — | Opinion of 5 December 2019 concerning (3aS,5S,6R,7aR,7bS,9aS,10R,12aS,12bS)-10-[(2S,3R,4R,5R)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-5,6-dihydroxy-7a,9a-dimethylhexadecahydro-3H-benzo[c]indeno[5,4-e]oxepin-3-one; 24-epibrassinolide, |
| --- | --- |

—

Opinion of 5 December 2019 concerning (3aS,5S,6R,7aR,7bS,9aS,10R,12aS,12bS)-10-[(2S,3R,4R,5R)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-5,6-dihydroxy-7a,9a-dimethylhexadecahydro-3H-benzo[c]indeno[5,4-e]oxepin-3-one; 24-epibrassinolide,

| — | Opinion of 5 December 2019 concerning 3-methylpyrazole, |
| --- | --- |

—

Opinion of 5 December 2019 concerning 3-methylpyrazole,

| — | Opinion of 5 December 2019 concerning carbendazim (ISO); methyl benzimidazol-2-ylcarbamate, |
| --- | --- |

—

Opinion of 5 December 2019 concerning carbendazim (ISO); methyl benzimidazol-2-ylcarbamate,

| — | Opinion of 5 December 2019 concerning cypermethrin cis/trans +/- 40/60; (RS)-α-cyano-3-phenoxybenzyl (1RS,3RS;1RS,3SR)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate, |
| --- | --- |

—

Opinion of 5 December 2019 concerning cypermethrin cis/trans +/- 40/60; (RS)-α-cyano-3-phenoxybenzyl (1RS,3RS;1RS,3SR)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate,

| — | Opinion of 5 December 2019 concerning imazamox (ISO); (RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid, |
| --- | --- |

—

Opinion of 5 December 2019 concerning imazamox (ISO); (RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid,

| — | Opinion of 5 December 2019 concerning tetrafluoroethylene, |
| --- | --- |

—

Opinion of 5 December 2019 concerning tetrafluoroethylene,

| — | Opinion of 5 December 2019 concerning thiamethoxam (ISO); 3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine, |
| --- | --- |

—

Opinion of 5 December 2019 concerning thiamethoxam (ISO); 3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine,

| — | Opinion of 5 December 2019 concerning trinexapac-ethyl (ISO); ethyl 4-[cyclopropyl(hydroxy)methylene]-3,5-dioxocyclohexanecarboxylate. |
| --- | --- |

—

Opinion of 5 December 2019 concerning trinexapac-ethyl (ISO); ethyl 4-[cyclopropyl(hydroxy)methylene]-3,5-dioxocyclohexanecarboxylate.

| (3) | Acute Toxicity Estimates (ATE) are mainly used to determine the classification for human health acute toxicity of mixtures containing substances classified for acute toxicity. The inclusion of harmonised ATE values in the entries listed in Annex VI to Regulation (EC) No 1272/2008 facilitates the harmonisation of the classification of mixtures and provides support for enforcement authorities. Following further scientific assessmentsof some substances, ATE values have been derived by the Agency for dicopper oxide, dicopper chloride trihydroxide, tetracopper hexahydroxide sulphate and tetracopper hexahydroxide sulphate hydrate, copper flakes (coated with aliphatic acid), copper(II) carbonate--copper(II) hydroxide (1:1), copper dihydroxide; copper(II) hydroxide, bordeaux mixture; reaction products of copper sulphate with calcium dihydroxide and copper sulphate pentahydrate, in addition to those proposed in the RAC opinions for other substances. Those ATE values should be inserted in the penultimate column of Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008. |
| --- | --- |

(3)

Acute Toxicity Estimates (ATE) are mainly used to determine the classification for human health acute toxicity of mixtures containing substances classified for acute toxicity. The inclusion of harmonised ATE values in the entries listed in Annex VI to Regulation (EC) No 1272/2008 facilitates the harmonisation of the classification of mixtures and provides support for enforcement authorities. Following further scientific assessmentsof some substances, ATE values have been derived by the Agency for dicopper oxide, dicopper chloride trihydroxide, tetracopper hexahydroxide sulphate and tetracopper hexahydroxide sulphate hydrate, copper flakes (coated with aliphatic acid), copper(II) carbonate--copper(II) hydroxide (1:1), copper dihydroxide; copper(II) hydroxide, bordeaux mixture; reaction products of copper sulphate with calcium dihydroxide and copper sulphate pentahydrate, in addition to those proposed in the RAC opinions for other substances. Those ATE values should be inserted in the penultimate column of Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008.

| (4) | Additional information was received by the Commission contesting the scientific assessment set out in the RAC opinions of 15 March 2019 concerning mancozeb, of 20 September 2019 concerning 4-methylpentan-2-one, and of 20 September 2019 concerning dimethomorph. That information was assessed by the Commission and was not found sufficient to cast doubts on the scientific analysis contained in the RAC opinions. |
| --- | --- |

(4)

Additional information was received by the Commission contesting the scientific assessment set out in the RAC opinions of 15 March 2019 concerning mancozeb, of 20 September 2019 concerning 4-methylpentan-2-one, and of 20 September 2019 concerning dimethomorph. That information was assessed by the Commission and was not found sufficient to cast doubts on the scientific analysis contained in the RAC opinions.

| (5) | The Commission therefore considers appropriate to introduce, update or delete the harmonised classification and labelling of certain substances. |
| --- | --- |

(5)

The Commission therefore considers appropriate to introduce, update or delete the harmonised classification and labelling of certain substances.

| (6) | Regulation (EC) No 1272/2008 should therefore be amended accordingly. |
| --- | --- |

(6)

Regulation (EC) No 1272/2008 should therefore be amended accordingly.

| (7) | Compliance with the new or updated harmonised classifications should not be required immediately as a certain period of time is necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new or revised classifications and to sell existing stocks subject to the pre-existing regulatory requirements. That period of time is also necessary to allow suppliers sufficient time to take the actions required to ensure continuing compliance with other legal requirements following the changes made under this Regulation. Such requirements may include those set out in point (f) of Article 22(1) of Regulation (EC) No 1907/2006 of the European Parliament and of the Council (3) or those set out in Article 50 of Regulation (EU) No 528/2012 of the European Parliament and of the Council (4). Suppliers should, however, have the possibility to apply the new or updated harmonised classifications, and to adapt the labelling and packaging accordingly, on a voluntary basis before the date of application of this Regulation and as of the date of entry into force to ensure a high level of protection of human health and of the environment and to provide sufficient flexibility to suppliers, |
| --- | --- |

(7)

Compliance with the new or updated harmonised classifications should not be required immediately as a certain period of time is necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new or revised classifications and to sell existing stocks subject to the pre-existing regulatory requirements. That period of time is also necessary to allow suppliers sufficient time to take the actions required to ensure continuing compliance with other legal requirements following the changes made under this Regulation. Such requirements may include those set out in point (f) of Article 22(1) of Regulation (EC) No 1907/2006 of the European Parliament and of the Council (3) or those set out in Article 50 of Regulation (EU) No 528/2012 of the European Parliament and of the Council (4). Suppliers should, however, have the possibility to apply the new or updated harmonised classifications, and to adapt the labelling and packaging accordingly, on a voluntary basis before the date of application of this Regulation and as of the date of entry into force to ensure a high level of protection of human health and of the environment and to provide sufficient flexibility to suppliers,

HAS ADOPTED THIS REGULATION:

Article 1

Amendments to Regulation (EC) No 1272/2008

Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.

Article 2

Entry into force and application

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

Official Journal of the European Union

It shall apply from 17 December 2022.

By way of derogation from the second paragraph of this Article, substances and mixtures may be classified, labelled and packaged in accordance with this Regulation from its date of entry into force.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 11 March 2021.

For the Commission

The President

Ursula VON DER LEYEN

---

(1)  
  OJ L 353, 31.12.2008, p. 1.

1

(2)  The opinions are accessible via the following website:https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/

2

(3)  Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006, p. 1).

3

(4)  Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ L 167, 27.6.2012, p. 1).

4

---

ANNEX

In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:

| (1) | the following entries are inserted:
















  Index No | Chemical Name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-
  factors and ATE | Notes |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) |
| ‘601-093-00-6 | 1,4-dimethylnaphthalene | 209-335-9 | 571-58-4 | Acute Tox. 4
  Asp. Tox. 1
  Eye Irrit. 2
  Aquatic Acute 1
  Aquatic Chronic 3 | H302
  H304
  H319
  H400
  H412 | GHS07
  GHS08
  GHS09
  Dgr | H302
  H304
  H319
  H410 | | oral: ATE = 1 300 mg/kg bw
  M = 1’ | |
| ‘601-094-00-1 | 1-isopropyl-4-methylbenzene;

  p-cymene | 202-796-7 | 99-87-6 | Flam. Liq. 3
  Acute Tox. 3
  Asp. Tox. 1
  Aquatic Chronic 2 | H226
  H331
  H304
  H411 | GHS02
  GHS06
  GHS08
  GHS09
  Dgr | H226
  H331
  H304
  H411 | | inhalation: ATE = 3 mg/l (vapours)’ | |
| ‘601-095-00-7 | p-mentha-1,3-diene; 1-isopropyl-4-methylcyclohexa-1,3-diene;
  alpha-terpinene | 202-795-1 | 99-86-5 | Flam. Liq. 3
  Acute Tox. 4
  Skin Sens. 1
  Asp. Tox. 1
  Aquatic Chronic 2 | H226
  H302
  H317
  H304
  H411 | GHS02
  GHS07
  GHS08
  GHS09
  Dgr | H226
  H302
  H317
  H304
  H411 | | oral: ATE = 1 680 mg/kg bw’ | |
| ‘602-110-00-X | tetrafluoroethylene | 204-126-9 | 116-14-3 | Carc. 1B | H350 | GHS08
  Dgr | H350’ | | | |
| ‘604-095-00-5 | 6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol;
  [DBMC] | 204-327-1 | 119-47-1 | Repr. 1B | H360F | GHS08
  Dgr | H360F’ | | | |
| ‘606-152-00-X | (5-chloro-2-methoxy-4-methyl-3-pyridyl)(4,5,6-trimethoxy-o-tolyl)methanone; pyriofenone | - | 688046-61-9 | Carc. 2
  Aquatic Chronic 1 | H351
  H410 | GHS08
  GHS09
  Wng | H351
  H410 | | M = 1’ | |
| ‘607-747-00-7 | 2,2-dibromo-2-cyanoacetamide; [DBNPA] | 233-539-7 | 10222-01-2 | Acute Tox. 2
  Acute Tox. 3
  STOT RE 1
  Skin Irrit. 2
  Eye Dam. 1
  Skin Sens. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H330
  H301
  H372 (respiratory tract) (inhalation)
  H315
  H318
  H317
  H400
  H410 | GHS06
  GHS08
  GHS05
  GHS09
  Dgr | H330
  H301
  H372 (respiratory tract) (inhalation)
  H315
  H318
  H317
  H410 | | inhalation: ATE = 0,24 mg/l (dusts or mists)
  oral: ATE = 118 mg/kg bw
  M = 1
  M = 1’ | |
| ‘607-748-00-2 | [S-(Z,E)]-5-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)-3-methylpenta-2,4-dienoic acid;

  S-abscisic acid | 244-319-5 | 21293-29-8 | Aquatic Acute 1
  Aquatic Chronic 1 | H400
  H410 | GHS09
  Wng | H410 | | M = 1
  M = 1’ | |
| ‘607-749-00-8 | methyl salicylate | 204-317-7 | 119-36-8 | Repr. 2
  Acute Tox. 4
  Skin Sens. 1B
  Aquatic Chronic 3 | H361d
  H302
  H317
  H412 | GHS07
  GHS08
  Wng | H361d
  H302
  H317
  H412 | | oral: ATE = 890 mg/kg bw’ | |
| ‘607-750-00-3 | citric acid | 201-069-1 | 77-92-9 | Eye Irrit. 2
  STOT SE 3 | H319
  H335 | GHS07
  Wng | H319
  H335’ | | | |
| ‘607-751-00-9 | ethametsulfuron-methyl (ISO);
  methyl 2-({[4-ethoxy-6-(methylamino)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)benzoate | - | 97780-06-8 | Eye Irrit. 2
  Aquatic Acute 1
  Aquatic Chronic 1 | H319
  H400
  H410 | GHS07
  GHS09
  Wng | H319
  H410 | | M = 1 000
  M = 100’ | |
| ‘607-752-00-4 | trinexapac-ethyl (ISO);
  ethyl 4-[cyclopropyl(hydroxy)methylene]-3,5-dioxocyclohexanecarboxylate | - | 95266-40-3 | STOT RE 2
  Skin Sens. 1B
  Aquatic Chronic 1 | H373 (gastrointestinal tract)
  H317
  H410 | GHS08
  GHS07
  GHS09
  Wng | H373 (gastrointestinal tract)
  H317
  H410 | | M = 1’ | |
| ‘607-753-00-X | (3aS,5S,6R,7aR,7bS,9aS,10R,12aS,12bS)-10-[(2S,3R,4R,5R)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-5,6-dihydroxy-7a,9a-dimethylhexadecahydro-3H-benzo[c]indeno[5,4-e]oxepin-3-one; 24-epibrassinolide | - | 78821-43-9 | Aquatic Chronic 4 | H413 | | H413’ | | | |
| ‘607-754-00-5 | benzyl salicylate | 204-262-9 | 118-58-1 | Skin Sens. 1B | H317 | GHS07
  Wng | H317’ | | | |
| ‘607-755-00-0 | (RS)-1-{1-ethyl-4-[4-mesyl-3-(2-methoxyethoxy)-o-toluoyl]pyrazol-5-yloxy}ethyl methyl carbonate;
  tolpyralate | - | 1101132-67-5 | Carc. 2
  Repr. 2
  STOT RE 2
  Aquatic Acute 1
  Aquatic Chronic 1 | H351
  H361fd
  H373 (eye)
  H400
  H410 | GHS08
  GHS09
  Wng | H351
  H361fd
  H373 (eye)
  H410 | | M = 10
  M = 100’ | |
| ‘613-337-00-9 | prothioconazole (ISO);
  2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione | - | 178928-70-6 | Aquatic Acute 1
  Aquatic Chronic 1 | H400
  H410 | GHS09
  Wng | H410 | | M = 10
  M = 1’ | |
| ‘613-338-00-4 | azamethiphos (ISO); S-[(6-chloro-2-oxooxazolo[4,5-b]pyridin-3(2H)-yl)methyl] O,O-dimethyl thiophosphate | 252-626-0 | 35575-96-3 | Carc. 2
  Acute Tox. 3
  Acute Tox. 4
  STOT SE 1
  Skin Sens. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H351
  H331
  H302
  H370 (nervous system)
  H317
  H400
  H410 | GHS06
  GHS08
  GHS09
  Dgr | H351
  H331
  H302
  H370 (nervous system)
  H317
  H410 | | inhalation: ATE = 0,5 mg/l (dusts or mists)
  oral: ATE = 500 mg/kg bw
  M = 1 000
  M = 1 000 ’ | |
| ‘613-339-00-X | 3-methylpyrazole | 215-925-7 | 1453-58-3 | Repr. 1B
  Acute Tox. 4
  STOT RE 2
  Skin Corr. 1
  Eye Dam. 1 | H360D
  H302
  H373 (lung)
  H314
  H318 | GHS08
  GHS07
  GHS05
  Dgr | H360D
  H302
  H373 (lung)
  H314 | | oral: ATE = 500 mg/kg bw’ | |
| ‘613-340-00-5 | clomazone (ISO); 2-(2-chlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one | - | 81777-89-1 | Acute Tox. 4
  Acute Tox. 4
  Aquatic Acute 1
  Aquatic Chronic 1 | H332
  H302
  H400
  H410 | GHS07
  GHS09
  Wng | H332
  H302
  H410 | | inhalation: ATE = 4,85 mg/l (dusts or mists)
  oral: ATE = 768 mg/kg bw
  M = 1
  M = 1’ | |
| ‘614-030-00-2 | emamectin benzoate (ISO); (4"R)-4"-deoxy-4"-(methylamino) avermectin B1 benzoate | - | 155569-91-8 | Acute Tox. 3
  Acute Tox. 3
  Acute Tox. 3
  STOT SE 1
  STOT RE 1
  Eye Dam. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H331
  H311
  H301
  H370 (nervous system)
  H372 (nervous system)
  H318
  H400
  H410 | GHS06
  GHS05
  GHS08
  GHS09
  Dgr | H331
  H311
  H301
  H370 (nervous system)
  H372 (nervous system)
  H318
  H410 | | inhalation:
  ATE = 0,663
  mg/l (dusts or mists)
  dermal:
  ATE = 300
  mg/kg bw
  oral: ATE =
  60 mg/kg bw
  STOT RE 1; H372: C ≥ 5 %; STOT RE 2; H373: 0,5 % ≤ C < 5 %
  M = 10 000
  M = 10 000 ’ | |
| ‘616-234-00-7 | N-methoxy-N-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide; pydiflumetofen | - | 1228284-64-7 | Carc. 2
  Repr. 2
  Aquatic Acute 1
  Aquatic Chronic 1 | H351
  H361f
  H400
  H410 | GHS08
  GHS09
  Wng | H351
  H361f
  H410 | | M = 1
  M = 1’ | |
| ‘616-235-00-2 | N-{2-[[1,1'-bi(cyclopropyl)]-2-yl]phenyl}-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide; sedaxane | - | 874967-67-6 | Carc. 2
  Aquatic Acute 1
  Aquatic Chronic 2 | H351
  H400
  H411 | GHS08
  GHS09
  Wng | H351
  H410 | | M = 1’ | |

(1)

the following entries are inserted:

Index No

Chemical Name

EC No

CAS No

Classification

Labelling

Specific Conc. Limits, M-
  factors and ATE

Notes

Hazard Class and Category Code(s)

Hazard statement Code(s)

Pictogram, Signal Word Code(s)

Hazard statement Code(s)

Suppl. Hazard statement Code(s)

‘601-093-00-6

1,4-dimethylnaphthalene

209-335-9

571-58-4

Acute Tox. 4

Asp. Tox. 1

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 3

H302

H304

H319

H400

H412

GHS07

GHS08

GHS09

Dgr

H302

H304

H319

H410

oral: ATE = 1 300 mg/kg bw

M = 1’

‘601-094-00-1

1-isopropyl-4-methylbenzene;

p-cymene

202-796-7

99-87-6

Flam. Liq. 3

Acute Tox. 3

Asp. Tox. 1

Aquatic Chronic 2

H226

H331

H304

H411

GHS02

GHS06

GHS08

GHS09

Dgr

H226

H331

H304

H411

inhalation: ATE = 3 mg/l (vapours)’

‘601-095-00-7

p-mentha-1,3-diene; 1-isopropyl-4-methylcyclohexa-1,3-diene;

alpha-terpinene

202-795-1

99-86-5

Flam. Liq. 3

Acute Tox. 4

Skin Sens. 1

Asp. Tox. 1

Aquatic Chronic 2

H226

H302

H317

H304

H411

GHS02

GHS07

GHS08

GHS09

Dgr

H226

H302

H317

H304

H411

oral: ATE = 1 680 mg/kg bw’

‘602-110-00-X

tetrafluoroethylene

204-126-9

116-14-3

Carc. 1B

H350

GHS08

Dgr

H350’

‘604-095-00-5

6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol;

[DBMC]

204-327-1

119-47-1

Repr. 1B

H360F

GHS08

Dgr

H360F’

‘606-152-00-X

(5-chloro-2-methoxy-4-methyl-3-pyridyl)(4,5,6-trimethoxy-o-tolyl)methanone; pyriofenone

-

688046-61-9

Carc. 2

Aquatic Chronic 1

H351

H410

GHS08

GHS09

Wng

H351

H410

M = 1’

‘607-747-00-7

2,2-dibromo-2-cyanoacetamide; [DBNPA]

233-539-7

10222-01-2

Acute Tox. 2

Acute Tox. 3

STOT RE 1

Skin Irrit. 2

Eye Dam. 1

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H330

H301

H372 (respiratory tract) (inhalation)

H315

H318

H317

H400

H410

GHS06

GHS08

GHS05

GHS09

Dgr

H330

H301

H372 (respiratory tract) (inhalation)

H315

H318

H317

H410

inhalation: ATE = 0,24 mg/l (dusts or mists)

oral: ATE = 118 mg/kg bw

M = 1

M = 1’

‘607-748-00-2

[S-(Z,E)]-5-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)-3-methylpenta-2,4-dienoic acid;

S-abscisic acid

244-319-5

21293-29-8

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 1

M = 1’

‘607-749-00-8

methyl salicylate

204-317-7

119-36-8

Repr. 2

Acute Tox. 4

Skin Sens. 1B

Aquatic Chronic 3

H361d

H302

H317

H412

GHS07

GHS08

Wng

H361d

H302

H317

H412

oral: ATE = 890 mg/kg bw’

‘607-750-00-3

citric acid

201-069-1

77-92-9

Eye Irrit. 2

STOT SE 3

H319

H335

GHS07

Wng

H319

H335’

‘607-751-00-9

ethametsulfuron-methyl (ISO);

methyl 2-({[4-ethoxy-6-(methylamino)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)benzoate

-

97780-06-8

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H319

H400

H410

GHS07

GHS09

Wng

H319

H410

M = 1 000

M = 100’

‘607-752-00-4

trinexapac-ethyl (ISO);

ethyl 4-[cyclopropyl(hydroxy)methylene]-3,5-dioxocyclohexanecarboxylate

-

95266-40-3

STOT RE 2

Skin Sens. 1B

Aquatic Chronic 1

H373 (gastrointestinal tract)

H317

H410

GHS08

GHS07

GHS09

Wng

H373 (gastrointestinal tract)

H317

H410

M = 1’

‘607-753-00-X

(3aS,5S,6R,7aR,7bS,9aS,10R,12aS,12bS)-10-[(2S,3R,4R,5R)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-5,6-dihydroxy-7a,9a-dimethylhexadecahydro-3H-benzo[c]indeno[5,4-e]oxepin-3-one; 24-epibrassinolide

-

78821-43-9

Aquatic Chronic 4

H413

H413’

‘607-754-00-5

benzyl salicylate

204-262-9

118-58-1

Skin Sens. 1B

H317

GHS07

Wng

H317’

‘607-755-00-0

(RS)-1-{1-ethyl-4-[4-mesyl-3-(2-methoxyethoxy)-o-toluoyl]pyrazol-5-yloxy}ethyl methyl carbonate;

tolpyralate

-

1101132-67-5

Carc. 2

Repr. 2

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H361fd

H373 (eye)

H400

H410

GHS08

GHS09

Wng

H351

H361fd

H373 (eye)

H410

M = 10

M = 100’

‘613-337-00-9

prothioconazole (ISO);

2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione

-

178928-70-6

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 10

M = 1’

‘613-338-00-4

azamethiphos (ISO); S-[(6-chloro-2-oxooxazolo[4,5-b]pyridin-3(2H)-yl)methyl] O,O-dimethyl thiophosphate

252-626-0

35575-96-3

Carc. 2

Acute Tox. 3

Acute Tox. 4

STOT SE 1

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H331

H302

H370 (nervous system)

H317

H400

H410

GHS06

GHS08

GHS09

Dgr

H351

H331

H302

H370 (nervous system)

H317

H410

inhalation: ATE = 0,5 mg/l (dusts or mists)

oral: ATE = 500 mg/kg bw

M = 1 000

M = 1 000 ’

‘613-339-00-X

3-methylpyrazole

215-925-7

1453-58-3

Repr. 1B

Acute Tox. 4

STOT RE 2

Skin Corr. 1

Eye Dam. 1

H360D

H302

H373 (lung)

H314

H318

GHS08

GHS07

GHS05

Dgr

H360D

H302

H373 (lung)

H314

oral: ATE = 500 mg/kg bw’

‘613-340-00-5

clomazone (ISO); 2-(2-chlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one

-

81777-89-1

Acute Tox. 4

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H332

H302

H400

H410

GHS07

GHS09

Wng

H332

H302

H410

inhalation: ATE = 4,85 mg/l (dusts or mists)

oral: ATE = 768 mg/kg bw

M = 1

M = 1’

‘614-030-00-2

emamectin benzoate (ISO); (4"R)-4"-deoxy-4"-(methylamino) avermectin B1 benzoate

-

155569-91-8

Acute Tox. 3

Acute Tox. 3

Acute Tox. 3

STOT SE 1

STOT RE 1

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H331

H311

H301

H370 (nervous system)

H372 (nervous system)

H318

H400

H410

GHS06

GHS05

GHS08

GHS09

Dgr

H331

H311

H301

H370 (nervous system)

H372 (nervous system)

H318

H410

inhalation:

ATE = 0,663

mg/l (dusts or mists)

dermal:

ATE = 300

mg/kg bw

oral: ATE =

60 mg/kg bw

STOT RE 1; H372: C ≥ 5 %; STOT RE 2; H373: 0,5 % ≤ C < 5 %

M = 10 000

M = 10 000 ’

‘616-234-00-7

N-methoxy-N-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide; pydiflumetofen

-

1228284-64-7

Carc. 2

Repr. 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H361f

H400

H410

GHS08

GHS09

Wng

H351

H361f

H410

M = 1

M = 1’

‘616-235-00-2

N-{2-[[1,1'-bi(cyclopropyl)]-2-yl]phenyl}-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide; sedaxane

-

874967-67-6

Carc. 2

Aquatic Acute 1

Aquatic Chronic 2

H351

H400

H411

GHS08

GHS09

Wng

H351

H410

M = 1’

| (2) | the entries corresponding to index numbers 005-007-00-2; 005-008-00-8; 005-011-00-4; 005-011-01-1; 005-011-02-9; 006-069-00-3; 006-076-00-1; 015-113-00-0; 028-007-00-4; 029-002-00-X; 029-015-00-0; 029-016-00-6; 029-017-00-1; 029-018-00-7; 029-019-01-X; 029-020-00-8; 029-021-00-3; 029-022-00-9; 029-023-00-4; 601-029-00-7; 601-096-00-2; 603-024-00-5; 603-066-00-4; 603-098-00-9; 606-004-00-4; 607-421-00-4; 607-424-00-0; 607-434-00-5; 608-058-00-4; 612-067-00-9; 612-252-00-4; 613-048-00-8; 613-102-00-0; 613-111-00-X; 613-166-00-X; 613-208-00-7; 613-267-00-9; 613-282-00-0; 616-032-00-9; 616-106-00-0 and 616-113-00-9 are replaced by the following entries respectively:
















  Index No | Chemical Name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M- factors and ATE | Notes |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) |
| ‘005-007-00-2 | boric acid [1]
  boric acid [2] | 233-139-2 [1]
  234-343-4 [2] | 10043-35-3 [1]
  11113-50-1 [2] | Repr. 1B | H360FD | GHS08
  Dgr | H360FD’ | | | |
| ‘005-008-00-8 | diboron trioxide | 215-125-8 | 1303-86-2 | Repr. 1B | H360FD | GHS08
  Dgr | H360FD’ | | | |
| ‘005-011-00-4 | tetraboron disodium heptaoxide, hydrate; [1]
  disodium tetraborate, anhydrous; [2]
  orthoboric acid, sodium salt [3]
  disodium tetraborate decahydrate [4]
  disodium tetraborate pentahydrate [5] | 235-541-3 [1]
  215-540-4 [2]
  237-560-2 [3]
  215-540-4 [4]
  215-540-4 [5] | 12267-73-1 [1]
  1330-43-4 [2]
  13840-56-7 [3]
  1303-96-4 [4]
  12179-04-3 [5] | Repr. 1B | H360FD | GHS08
  Dgr | H360FD’ | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| ‘006-069-00-3 | thiophanate-methyl (ISO);
  dimethyl (1,2-phenylenedicarbamothioyl)biscarbamate;
  dimethyl 4,4′-(o-phenylene)bis(3-thioallophanate) | 245-740-7 | 23564-05-8 | Carc. 2
  Muta. 2
  Acute Tox. 4
  Skin Sens. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H351
  H341
  H332
  H317
  H400
  H410 | GHS08
  GHS07
  GHS09
  Wng | H351
  H341
  H332
  H317
  H410 | | inhalation: ATE = 1,7 mg/l
  (dusts and mists)
  M = 10
  M = 10’ | |
| ‘006-076-00-1 | mancozeb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt | - | 8018-01-7 | Carc. 2
  Repr. 1B
  STOT RE 2
  Skin Sens. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H351
  H360D
  H373 (thyroid, nervous system)
  H317
  H400
  H410 | GHS08
  GHS07
  GHS09
  Dgr | H351
  H360D
  H373 (thyroid, nervous system)
  H317
  H410 | | M = 10
  M = 10’ | |
| ‘015-113-00-0 | tolclofos-methyl (ISO);

  O-(2,6-dichloro-p-tolyl) O,O-dimethyl thiophosphate | 260-515-3 | 57018-04-9 | Skin Sens. 1B
  Aquatic Acute 1
  Aquatic Chronic 1 | H317
  H400
  H410 | GHS07
  GHS09
  Wng | H317
  H410 | | M = 1
  M = 1’ | |
| ‘028-007-00-4 | trinickel disulfide;
  nickel subsulfide; [1]
  heazlewoodite [2] | 234-829-6 [1]
  - [2] | 12035-72-2 [1]
  12035-71-1 [2] | Carc. 1A
  Muta. 2
  Acute Tox. 3
  STOT RE 1
  Skin Sens. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H350i
  H341
  H331
  H372**
  H317
  H400
  H410 | GHS08
  GHS06
  GHS09
  Dgr | H350i
  H341
  H331
  H372**
  H317
  H410 | | inhalation:
  ATE = 0,92 mg/l
  (dusts or mists)’ | |
| ‘029-002-00-X | dicopper oxide;
  copper (I) oxide | 215-270-7 | 1317-39-1 | Acute Tox. 4
  Acute Tox. 4
  Eye Dam. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H332
  H302
  H318
  H400
  H410 | GHS07
  GHS05
  GHS09
  Dgr | H332
  H302
  H318
  H410 | | inhalation: ATE = 3,34 mg/l (dusts or mists)
  oral: ATE = 500 mg/kg bw
  M = 100
  M = 10’ | |
| ‘029-015-00-0 | copper thiocyanate | 214-183-1 | 1111-67-7 | Aquatic Acute 1
  Aquatic Chronic 1 | H400
  H410 | GHS09
  Wng | H410 | EUH032 | M = 10
  M = 10’ | |
| ‘029-016-00-6 | copper(II) oxide | 215-269-1 | 1317-38-0 | Aquatic Acute 1
  Aquatic Chronic 1 | H400
  H410 | GHS09
  Wng | H410 | | M = 100
  M = 10’ | |
| ‘029-017-00-1 | dicopper chloride trihydroxide | 215-572-9 | 1332-65-6 | Acute Tox. 4
  Acute Tox. 3
  Aquatic Acute 1
  Aquatic Chronic 1 | H332
  H301
  H400
  H410 | GHS06
  GHS09
  Dgr | H332
  H301
  H410 | | inhalation: ATE = 2,83 mg/l (dusts or mists)
  oral: ATE = 299 mg/kg bw
  M = 10
  M = 10’ | |
| ‘029-018-00-7 | tetracopper hexahydroxide sulphate; [1]
  tetracopper hexahydroxide sulphate hydrate [2] | 215-582-3 [1]
  215-582-3 [2] | 1333-22-8 [1]
  12527-76-3 [2] | Acute Tox. 4
  Aquatic Acute 1
  Aquatic Chronic 1 | H302
  H400
  H410 | GHS07
  GHS09
  Wng | H302
  H410 | | oral: ATE = 500 mg/kg bw
  M = 10
  M = 10’ | |
| ‘029-019-01-X | copper flakes (coated with aliphatic acid) | - | - | Acute Tox. 3
  Acute Tox. 4
  Eye Irrit. 2
  Aquatic Acute 1
  Aquatic Chronic 1 | H331
  H302
  H319
  H400
  H410 | GHS06
  GHS09
  Dgr | H331
  H302
  H319
  H410 | | inhalation: ATE = 0,733 mg/l (dusts or mists)
  oral: ATE = 500 mg/kg bw
  M = 10
  M = 10’ | |
| ‘029-020-00-8 | copper(II) carbonate—copper(II) hydroxide (1:1) | 235-113-6 | 12069-69-1 | Acute Tox. 4
  Acute Tox. 4
  Eye Irrit. 2
  Aquatic Acute 1
  Aquatic Chronic 1 | H332
  H302
  H319
  H400
  H410 | GHS07
  GHS09
  Wng | H332
  H302
  H319
  H410 | | inhalation: ATE = 1,2 mg/l (dusts or mists)
  oral: ATE = 500 mg/kg bw
  M = 10
  M = 10’ | |
| ‘029-021-00-3 | copper dihydroxide;
  copper(II) hydroxide | 243-815-9 | 20427-59-2 | Acute Tox. 2
  Acute Tox. 4
  Eye Dam. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H330
  H302
  H318
  H400
  H410 | GHS06
  GHS05
  GHS09
  Dgr | H330
  H302
  H318
  H410 | | inhalation: ATE = 0,47 mg/l (dusts or mists)
  oral: ATE = 500 mg/kg bw
  M = 10
  M = 10’ | |
| ‘029-022-00-9 | bordeaux mixture;
  reaction products of copper sulphate with calcium dihydroxide | - | 8011-63-0 | Acute Tox. 4
  Eye Dam. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H332
  H318
  H400
  H410 | GHS07
  GHS05
  GHS09
  Dgr | H332
  H318
  H410 | | inhalation: ATE = 1,97 mg/l (dusts or mists)
  M = 10
  M = 1’ | |
| ‘029-023-00-4 | copper sulphate pentahydrate | 231-847-6 | 7758-99-8 | Acute Tox. 4
  Eye Dam. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H302
  H318
  H400
  H410 | GHS07
  GHS05
  GHS09
  Dgr | H302
  H318
  H410 | | oral: ATE = 481 mg/kg bw
  M = 10
  M = 1’ | |
| ‘601-029-00-7 | dipentene;
  limonene [1]
  (S)-p-mentha-1,8-diene; l-limonene [2]

  trans-1-methyl-4-(1-methylvinyl)cyclohexene; [3]
  (±)-1-methyl-4-(1-methylvinyl)cyclohexene [4] | 205-341-0 [1]
  227-815-6 [2]
  229-977-3 [3]
  231-732-0 [4] | 138-86-3 [1]
  5989-54-8 [2]
  6876-12-6 [3]
  7705-14-8 [4] | Flam. Liq. 3
  Skin Irrit. 2
  Skin Sens. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H226
  H315
  H317
  H400
  H410 | GHS02
  GHS07
  GHS09
  Wng | H226
  H315
  H317
  H410 | | | C’ |
| ‘601-096-00-2 | (R)-p-mentha-1,8-diene;
  d-limonene | 227-813-5 | 5989-27-5 | Flam. Liq. 3
  Skin Irrit. 2
  Skin Sens. 1B
  Asp. Tox. 1
  Aquatic Acute 1
  Aquatic Chronic 3 | H226
  H315
  H317
  H304
  H400
  H412 | GHS02
  GHS07
  GHS08
  GHS09
  Dgr | H226
  H315
  H317
  H304
  H410 | | M = 1’ | |
| ‘603-024-00-5 | 1,4-dioxane | 204-661-8 | 123-91-1 | Flam. Liq. 2
  Carc. 1B
  STOT SE 3
  Eye Irrit. 2 | H225
  H350
  H335
  H319 | GHS02
  GHS08
  GHS07
  Dgr | H225
  H350
  H335
  H319 | EUH019
  EUH066 | | D’ |
| ‘603-066-00-4 | 7-oxa-3-oxiranylbicyclo[4.1.0]heptane; 1,2-epoxy-4-epoxyethylcyclohexane; 4-vinylcyclohexene diepoxide | 203-437-7 | 106-87-6 | Carc. 1B
  Muta. 2
  Repr. 1B
  Acute Tox. 3
  Acute Tox. 4 | H350
  H341
  H360F
  H331
  H302 | GHS08
  GHS06
  Dgr | H350
  H341
  H360F
  H331
  H302 | | inhalation: ATE = 0,5 mg/l (dusts or mists)
  oral: ATE = 1 847 mg/kg bw’ | |
| ‘603-098-00-9 | 2-phenoxyethanol | 204-589-7 | 122-99-6 | Acute Tox. 4
  STOT SE 3
  Eye Dam. 1 | H302
  H335
  H318 | GHS05
  GHS07
  Dgr | H302
  H335
  H318 | | oral:
  ATE = 1 394 mg/kg bw’ | |
| ‘606-004-00-4 | 4-methylpentan-2-one; isobutyl methyl ketone | 203-550-1 | 108-10-1 | Flam. Liq. 2
  Carc. 2
  Acute Tox. 4
  STOT SE 3
  Eye Irrit. 2 | H225
  H351
  H332
  H336
  H319 | GHS02
  GHS07
  GHS08
  Dgr | H225
  H351
  H332
  H336
  H319 | EUH066 | inhalation: ATE = 11 mg/l (vapours)’ | |
| ‘607-421-00-4 | cypermethrin (ISO);
  α-cyano-3-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate; cypermethrin cis/trans +/- 40/60 | 257-842-9 | 52315-07-8 | Acute Tox. 4
  Acute Tox. 4
  STOT SE 3
  STOT RE 2
  Aquatic Acute 1
  Aquatic Chronic 1 | H332
  H302
  H335
  H373 (nervous system)
  H400
  H410 | GHS07
  GHS08
  GHS09
  Wng | H332
  H302
  H335
  H373 (nervous system)
  H410 | | oral; ATE = 500 mg/kg bw
  inhalation; ATE = 3,3 mg/l (dusts or mists)
  M = 100000
  M = 100000’ | |
| ‘607-424-00-0 | trifloxystrobin (ISO); methyl (E)-methoxyimino-{(E)-α-[1-(α,α,α-trifluoro-m-tolyl)ethylideneaminooxy]-o-tolyl}acetate | - | 141517-21-7 | Lact.
  Skin Sens. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H362
  H317
  H400
  H410 | GHS07
  GHS09
  Wng | H362
  H317
  H410 | | M = 100
  M = 10’ | |
| ‘607-434-00-5 | mecoprop-P (ISO) [1] and its salts;
  (R)-2-(4-chloro-2-methylphenoxy)propionic acid [1] and its salts | 240-539-0 [1] | 16484-77-8 [1] | Acute Tox. 4
  Eye Dam. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H302
  H318
  H400
  H410 | GHS07
  GHS05
  GHS09
  Dgr | H302
  H318
  H410 | | oral: ATE = 431 mg/kg bw
  M = 10
  M = 10’ | |
| ‘608-058-00-4 | esfenvalerate (ISO);
  (S)-α-cyano-3-phenoxybenzyl-(S)-2-(4-chlorophenyl)-3-methylbutyrate | - | 66230-04-4 | Acute Tox. 3
  Acute Tox. 3
  STOT SE 1
  STOT RE 2
  Skin Sens. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H331
  H301
  H370 (nervous system)
  H373
  H317
  H400
  H410 | GHS06
  GHS08
  GHS09
  Dgr | H331
  H301
  H370 (nervous system)
  H373
  H317
  H410 | | oral; ATE = 88,5 mg/kg bw
  inhalation; ATE = 0,53 mg/l (dusts or mists)
  M = 10 000
  M = 10 000 ’ | |
| ‘612-067-00-9 | 3-aminomethyl-3,5,5-trimethylcyclohexylamine | 220-666-8 | 2855-13-2 | Acute Tox. 4
  Skin Corr. 1B
  Eye Dam. 1
  Skin Sens. 1A | H302
  H314
  H318
  H317 | GHS05
  GHS07
  Dgr | H302
  H314
  H317 | | oral: ATE = 1 030 mg/kg bw
  Skin Sens. 1A; H317: C ≥ 0,001 %’ | |
| ‘612-252-00-4 | imidacloprid (ISO);
  (E)-1-(6-chloro-3-pyridylmethyl)-N-nitroimidazolidin-2-ylideneamine;
  (2E)-1-[(6-chloropyridin-3-yl) methyl]-N-nitroimidazolidin-2-imine | 428-040-8 | 138261-41-3 | Acute Tox. 3
  Aquatic Acute 1
  Aquatic Chronic 1 | H301
  H400
  H410 | GHS06
  GHS09
  Dgr | H301
  H410 | | oral: ATE = 131 mg/kg bw
  M = 100
  M = 1 000 ’ | |
| ‘613-048-00-8 | carbendazim (ISO); methyl benzimidazol-2-ylcarbamate | 234-232-0 | 10605-21-7 | Muta. 1B
  Repr. 1B
  Skin Sens. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H340
  H360FD
  H317
  H400
  H410 | GHS07
  GHS08
  GHS09
  Dgr | H340
  H360FD
  H317
  H410 | | M = 10
  M = 10’ | |
| ‘613-102-00-0 | dimethomorph (ISO); (E,Z)-4-(3-(4-chlorophenyl)-3-(3,4-dimethoxyphenyl)acryloyl)morpholine | 404-200-2 | 110488-70-5 | Repr. 1B
  Aquatic Chronic 2 | H360F
  H411 | GHS08
  GHS09
  Dgr | H360F
  H411’ | | | |
| ‘613-111-00-X | 1,2,4-triazole | 206-022-9 | 288-88-0 | Repr. 1B
  Acute Tox. 4
  Eye Irrit. 2 | H360FD
  H302
  H319 | GHS08
  GHS07
  Dgr | H360FD
  H302
  H319 | | oral: ATE = 1 320 mg/kg bw’ | |
| ‘613-166-00-X | flumioxazin (ISO);

  N-(7-fluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl-2H-1,4-benzoxazin-6-yl)cyclohex-1-ene-1,2-dicarboximide | - | 103361-09-7 | Repr. 2
  Aquatic Acute 1
  Aquatic Chronic 1 | H361d
  H400
  H410 | GHS08
  GHS09
  Wng | H361d
  H410 | | M = 1 000
  M = 1 000 ’ | |
| ‘613-208-00-7 | imazamox (ISO);
  (RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid | - | 114311-32-9 | Repr. 2
  Aquatic Acute 1
  Aquatic Chronic 1 | H361d
  H400
  H410 | GHS08
  GHS09
  Wng | H361d
  H410 | | M = 10
  M = 10’ | |
| ‘613-267-00-9 | thiamethoxam (ISO);
  3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine | 428-650-4 | 153719-23-4 | Repr. 2
  Acute Tox. 4
  Aquatic Acute 1
  Aquatic Chronic 1 | H361fd
  H302
  H400
  H410 | GHS07
  GHS08
  GHS09
  Wng | H361fd
  H302
  H410 | | oral: ATE = 780 mg/kg bw
  M = 10
  M = 10’ | |
| ‘613-282-00-0 | triticonazole (ISO);
  (RS)-(E)-5-(4-chlorobenzylidene)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-methyl)cyclopentanol | - | 138182-18-0 | Repr. 2
  STOT RE 2
  Aquatic Acute 1
  Aquatic Chronic 1 | H361f
  H373
  H400
  H410 | GHS08
  GHS09
  Wng | H361f
  H373
  H410 | | M = 1
  M = 1’ | |
| ‘616-032-00-9 | diflufenican (ISO);

  N-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide; 2′,4′-difluoro-2-(α,α,α-trifluoro-m-tolyloxy) nicotinanilide | - | 83164-33-4 | Aquatic Acute 1
  Aquatic Chronic 1 | H400
  H410 | GHS09
  Wng | H410 | | M = 10 000
  M = 1 000 ’ | |
| ‘616-106-00-0 | phenmedipham (ISO); methyl 3-(3-methylcarbaniloyloxy)carbanilate | 237-199-0 | 13684-63-4 | Aquatic Acute 1
  Aquatic Chronic 1 | H400
  H410 | GHS09
  Wng | H410 | | M = 10
  M = 10’ | |
| ‘616-113-00-9 | desmedipham (ISO);
  ethyl 3-phenylcarbamoyloxyphenylcarbamate | 237-198-5 | 13684-56-5 | Repr. 2
  Aquatic Acute 1
  Aquatic Chronic 1 | H361d
  H400
  H410 | GHS08
  GHS09
  Wng | H361d
  H410 | | M = 10
  M = 10’ | |

(2)

the entries corresponding to index numbers 005-007-00-2; 005-008-00-8; 005-011-00-4; 005-011-01-1; 005-011-02-9; 006-069-00-3; 006-076-00-1; 015-113-00-0; 028-007-00-4; 029-002-00-X; 029-015-00-0; 029-016-00-6; 029-017-00-1; 029-018-00-7; 029-019-01-X; 029-020-00-8; 029-021-00-3; 029-022-00-9; 029-023-00-4; 601-029-00-7; 601-096-00-2; 603-024-00-5; 603-066-00-4; 603-098-00-9; 606-004-00-4; 607-421-00-4; 607-424-00-0; 607-434-00-5; 608-058-00-4; 612-067-00-9; 612-252-00-4; 613-048-00-8; 613-102-00-0; 613-111-00-X; 613-166-00-X; 613-208-00-7; 613-267-00-9; 613-282-00-0; 616-032-00-9; 616-106-00-0 and 616-113-00-9 are replaced by the following entries respectively:

Index No

Chemical Name

EC No

CAS No

Classification

Labelling

Specific Conc. Limits, M- factors and ATE

Notes

Hazard Class and Category Code(s)

Hazard statement Code(s)

Pictogram, Signal Word Code(s)

Hazard statement Code(s)

Suppl. Hazard statement Code(s)

‘005-007-00-2

boric acid [1]

boric acid [2]

233-139-2 [1]

234-343-4 [2]

10043-35-3 [1]

11113-50-1 [2]

Repr. 1B

H360FD

GHS08

Dgr

H360FD’

‘005-008-00-8

diboron trioxide

215-125-8

1303-86-2

Repr. 1B

H360FD

GHS08

Dgr

H360FD’

‘005-011-00-4

tetraboron disodium heptaoxide, hydrate; [1]

disodium tetraborate, anhydrous; [2]

orthoboric acid, sodium salt [3]

disodium tetraborate decahydrate [4]

disodium tetraborate pentahydrate [5]

235-541-3 [1]

215-540-4 [2]

237-560-2 [3]

215-540-4 [4]

215-540-4 [5]

12267-73-1 [1]

1330-43-4 [2]

13840-56-7 [3]

1303-96-4 [4]

12179-04-3 [5]

Repr. 1B

H360FD

GHS08

Dgr

H360FD’

‘006-069-00-3

thiophanate-methyl (ISO);

dimethyl (1,2-phenylenedicarbamothioyl)biscarbamate;

dimethyl 4,4′-(o-phenylene)bis(3-thioallophanate)

245-740-7

23564-05-8

Carc. 2

Muta. 2

Acute Tox. 4

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H341

H332

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H341

H332

H317

H410

inhalation: ATE = 1,7 mg/l

(dusts and mists)

M = 10

M = 10’

‘006-076-00-1

mancozeb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt

-

8018-01-7

Carc. 2

Repr. 1B

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H360D

H373 (thyroid, nervous system)

H317

H400

H410

GHS08

GHS07

GHS09

Dgr

H351

H360D

H373 (thyroid, nervous system)

H317

H410

M = 10

M = 10’

‘015-113-00-0

tolclofos-methyl (ISO);

O-(2,6-dichloro-p-tolyl) O,O-dimethyl thiophosphate

260-515-3

57018-04-9

Skin Sens. 1B

Aquatic Acute 1

Aquatic Chronic 1

H317

H400

H410

GHS07

GHS09

Wng

H317

H410

M = 1

M = 1’

‘028-007-00-4

trinickel disulfide;

nickel subsulfide; [1]

heazlewoodite [2]

234-829-6 [1]

- [2]

12035-72-2 [1]

12035-71-1 [2]

Carc. 1A

Muta. 2

Acute Tox. 3

STOT RE 1

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H350i

H341

H331

H372**

H317

H400

H410

GHS08

GHS06

GHS09

Dgr

H350i

H341

H331

H372**

H317

H410

inhalation:

ATE = 0,92 mg/l

(dusts or mists)’

‘029-002-00-X

dicopper oxide;

copper (I) oxide

215-270-7

1317-39-1

Acute Tox. 4

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H332

H302

H318

H400

H410

GHS07

GHS05

GHS09

Dgr

H332

H302

H318

H410

inhalation: ATE = 3,34 mg/l (dusts or mists)

oral: ATE = 500 mg/kg bw

M = 100

M = 10’

‘029-015-00-0

copper thiocyanate

214-183-1

1111-67-7

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

EUH032

M = 10

M = 10’

‘029-016-00-6

copper(II) oxide

215-269-1

1317-38-0

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 100

M = 10’

‘029-017-00-1

dicopper chloride trihydroxide

215-572-9

1332-65-6

Acute Tox. 4

Acute Tox. 3

Aquatic Acute 1

Aquatic Chronic 1

H332

H301

H400

H410

GHS06

GHS09

Dgr

H332

H301

H410

inhalation: ATE = 2,83 mg/l (dusts or mists)

oral: ATE = 299 mg/kg bw

M = 10

M = 10’

‘029-018-00-7

tetracopper hexahydroxide sulphate; [1]

tetracopper hexahydroxide sulphate hydrate [2]

215-582-3 [1]

215-582-3 [2]

1333-22-8 [1]

12527-76-3 [2]

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H302

H400

H410

GHS07

GHS09

Wng

H302

H410

oral: ATE = 500 mg/kg bw

M = 10

M = 10’

‘029-019-01-X

copper flakes (coated with aliphatic acid)

-

-

Acute Tox. 3

Acute Tox. 4

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H331

H302

H319

H400

H410

GHS06

GHS09

Dgr

H331

H302

H319

H410

inhalation: ATE = 0,733 mg/l (dusts or mists)

oral: ATE = 500 mg/kg bw

M = 10

M = 10’

‘029-020-00-8

copper(II) carbonate—copper(II) hydroxide (1:1)

235-113-6

12069-69-1

Acute Tox. 4

Acute Tox. 4

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H332

H302

H319

H400

H410

GHS07

GHS09

Wng

H332

H302

H319

H410

inhalation: ATE = 1,2 mg/l (dusts or mists)

oral: ATE = 500 mg/kg bw

M = 10

M = 10’

‘029-021-00-3

copper dihydroxide;

copper(II) hydroxide

243-815-9

20427-59-2

Acute Tox. 2

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H330

H302

H318

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H302

H318

H410

inhalation: ATE = 0,47 mg/l (dusts or mists)

oral: ATE = 500 mg/kg bw

M = 10

M = 10’

‘029-022-00-9

bordeaux mixture;

reaction products of copper sulphate with calcium dihydroxide

-

8011-63-0

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H332

H318

H400

H410

GHS07

GHS05

GHS09

Dgr

H332

H318

H410

inhalation: ATE = 1,97 mg/l (dusts or mists)

M = 10

M = 1’

‘029-023-00-4

copper sulphate pentahydrate

231-847-6

7758-99-8

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H302

H318

H400

H410

GHS07

GHS05

GHS09

Dgr

H302

H318

H410

oral: ATE = 481 mg/kg bw

M = 10

M = 1’

‘601-029-00-7

dipentene;

limonene [1]

(S)-p-mentha-1,8-diene; l-limonene [2]

trans-1-methyl-4-(1-methylvinyl)cyclohexene; [3]

(±)-1-methyl-4-(1-methylvinyl)cyclohexene [4]

205-341-0 [1]

227-815-6 [2]

229-977-3 [3]

231-732-0 [4]

138-86-3 [1]

5989-54-8 [2]

6876-12-6 [3]

7705-14-8 [4]

Flam. Liq. 3

Skin Irrit. 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H226

H315

H317

H400

H410

GHS02

GHS07

GHS09

Wng

H226

H315

H317

H410

C’

‘601-096-00-2

(R)-p-mentha-1,8-diene;

d-limonene

227-813-5

5989-27-5

Flam. Liq. 3

Skin Irrit. 2

Skin Sens. 1B

Asp. Tox. 1

Aquatic Acute 1

Aquatic Chronic 3

H226

H315

H317

H304

H400

H412

GHS02

GHS07

GHS08

GHS09

Dgr

H226

H315

H317

H304

H410

M = 1’

‘603-024-00-5

1,4-dioxane

204-661-8

123-91-1

Flam. Liq. 2

Carc. 1B

STOT SE 3

Eye Irrit. 2

H225

H350

H335

H319

GHS02

GHS08

GHS07

Dgr

H225

H350

H335

H319

EUH019

EUH066

D’

‘603-066-00-4

7-oxa-3-oxiranylbicyclo[4.1.0]heptane; 1,2-epoxy-4-epoxyethylcyclohexane; 4-vinylcyclohexene diepoxide

203-437-7

106-87-6

Carc. 1B

Muta. 2

Repr. 1B

Acute Tox. 3

Acute Tox. 4

H350

H341

H360F

H331

H302

GHS08

GHS06

Dgr

H350

H341

H360F

H331

H302

inhalation: ATE = 0,5 mg/l (dusts or mists)

oral: ATE = 1 847 mg/kg bw’

‘603-098-00-9

2-phenoxyethanol

204-589-7

122-99-6

Acute Tox. 4

STOT SE 3

Eye Dam. 1

H302

H335

H318

GHS05

GHS07

Dgr

H302

H335

H318

oral:

ATE = 1 394 mg/kg bw’

‘606-004-00-4

4-methylpentan-2-one; isobutyl methyl ketone

203-550-1

108-10-1

Flam. Liq. 2

Carc. 2

Acute Tox. 4

STOT SE 3

Eye Irrit. 2

H225

H351

H332

H336

H319

GHS02

GHS07

GHS08

Dgr

H225

H351

H332

H336

H319

EUH066

inhalation: ATE = 11 mg/l (vapours)’

‘607-421-00-4

cypermethrin (ISO);

α-cyano-3-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate; cypermethrin cis/trans +/- 40/60

257-842-9

52315-07-8

Acute Tox. 4

Acute Tox. 4

STOT SE 3

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H332

H302

H335

H373 (nervous system)

H400

H410

GHS07

GHS08

GHS09

Wng

H332

H302

H335

H373 (nervous system)

H410

oral; ATE = 500 mg/kg bw

inhalation; ATE = 3,3 mg/l (dusts or mists)

M = 100000

M = 100000’

‘607-424-00-0

trifloxystrobin (ISO); methyl (E)-methoxyimino-{(E)-α-[1-(α,α,α-trifluoro-m-tolyl)ethylideneaminooxy]-o-tolyl}acetate

-

141517-21-7

Lact.

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H362

H317

H400

H410

GHS07

GHS09

Wng

H362

H317

H410

M = 100

M = 10’

‘607-434-00-5

mecoprop-P (ISO) [1] and its salts;

(R)-2-(4-chloro-2-methylphenoxy)propionic acid [1] and its salts

240-539-0 [1]

16484-77-8 [1]

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H302

H318

H400

H410

GHS07

GHS05

GHS09

Dgr

H302

H318

H410

oral: ATE = 431 mg/kg bw

M = 10

M = 10’

‘608-058-00-4

esfenvalerate (ISO);

(S)-α-cyano-3-phenoxybenzyl-(S)-2-(4-chlorophenyl)-3-methylbutyrate

-

66230-04-4

Acute Tox. 3

Acute Tox. 3

STOT SE 1

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H331

H301

H370 (nervous system)

H373

H317

H400

H410

GHS06

GHS08

GHS09

Dgr

H331

H301

H370 (nervous system)

H373

H317

H410

oral; ATE = 88,5 mg/kg bw

inhalation; ATE = 0,53 mg/l (dusts or mists)

M = 10 000

M = 10 000 ’

‘612-067-00-9

3-aminomethyl-3,5,5-trimethylcyclohexylamine

220-666-8

2855-13-2

Acute Tox. 4

Skin Corr. 1B

Eye Dam. 1

Skin Sens. 1A

H302

H314

H318

H317

GHS05

GHS07

Dgr

H302

H314

H317

oral: ATE = 1 030 mg/kg bw

Skin Sens. 1A; H317: C ≥ 0,001 %’

‘612-252-00-4

imidacloprid (ISO);

(E)-1-(6-chloro-3-pyridylmethyl)-N-nitroimidazolidin-2-ylideneamine;

(2E)-1-[(6-chloropyridin-3-yl) methyl]-N-nitroimidazolidin-2-imine

428-040-8

138261-41-3

Acute Tox. 3

Aquatic Acute 1

Aquatic Chronic 1

H301

H400

H410

GHS06

GHS09

Dgr

H301

H410

oral: ATE = 131 mg/kg bw

M = 100

M = 1 000 ’

‘613-048-00-8

carbendazim (ISO); methyl benzimidazol-2-ylcarbamate

234-232-0

10605-21-7

Muta. 1B

Repr. 1B

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H340

H360FD

H317

H400

H410

GHS07

GHS08

GHS09

Dgr

H340

H360FD

H317

H410

M = 10

M = 10’

‘613-102-00-0

dimethomorph (ISO); (E,Z)-4-(3-(4-chlorophenyl)-3-(3,4-dimethoxyphenyl)acryloyl)morpholine

404-200-2

110488-70-5

Repr. 1B

Aquatic Chronic 2

H360F

H411

GHS08

GHS09

Dgr

H360F

H411’

‘613-111-00-X

1,2,4-triazole

206-022-9

288-88-0

Repr. 1B

Acute Tox. 4

Eye Irrit. 2

H360FD

H302

H319

GHS08

GHS07

Dgr

H360FD

H302

H319

oral: ATE = 1 320 mg/kg bw’

‘613-166-00-X

flumioxazin (ISO);

N-(7-fluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl-2H-1,4-benzoxazin-6-yl)cyclohex-1-ene-1,2-dicarboximide

-

103361-09-7

Repr. 2

Aquatic Acute 1

Aquatic Chronic 1

H361d

H400

H410

GHS08

GHS09

Wng

H361d

H410

M = 1 000

M = 1 000 ’

‘613-208-00-7

imazamox (ISO);

(RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid

-

114311-32-9

Repr. 2

Aquatic Acute 1

Aquatic Chronic 1

H361d

H400

H410

GHS08

GHS09

Wng

H361d

H410

M = 10

M = 10’

‘613-267-00-9

thiamethoxam (ISO);

3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine

428-650-4

153719-23-4

Repr. 2

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H361fd

H302

H400

H410

GHS07

GHS08

GHS09

Wng

H361fd

H302

H410

oral: ATE = 780 mg/kg bw

M = 10

M = 10’

‘613-282-00-0

triticonazole (ISO);

(RS)-(E)-5-(4-chlorobenzylidene)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-methyl)cyclopentanol

-

138182-18-0

Repr. 2

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H361f

H373

H400

H410

GHS08

GHS09

Wng

H361f

H373

H410

M = 1

M = 1’

‘616-032-00-9

diflufenican (ISO);

N-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide; 2′,4′-difluoro-2-(α,α,α-trifluoro-m-tolyloxy) nicotinanilide

-

83164-33-4

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 10 000

M = 1 000 ’

‘616-106-00-0

phenmedipham (ISO); methyl 3-(3-methylcarbaniloyloxy)carbanilate

237-199-0

13684-63-4

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 10

M = 10’

‘616-113-00-9

desmedipham (ISO);

ethyl 3-phenylcarbamoyloxyphenylcarbamate

237-198-5

13684-56-5

Repr. 2

Aquatic Acute 1

Aquatic Chronic 1

H361d

H400

H410

GHS08

GHS09

Wng

H361d

H410

M = 10

M = 10’

| (3) | the entry corresponding to index number 015-192-00-1 is deleted. |
| --- | --- |

(3)

the entry corresponding to index number 015-192-00-1 is deleted.

---